🔬TODAY’S BREAKTHROUGH
What happens when you combine two of the most studied longevity drugs?
A new study reveals that pairing rapamycin with trametinib delivers more than either drug alone, extending lifespan and reducing age-related disease in mice.
The Discovery:
Scientists at the Max Planck Institute for Biology of Ageing found that combining rapamycin and trametinib increased the lifespan of aged mice by nearly 30%.
Each drug independently extended life, but together they had additive effects, with benefits to healthspan, immune function, and tumor suppression.
The Science:
Rapamycin inhibits mTOR (mechanistic target of rapamycin), a nutrient-sensing protein that promotes aging when chronically overactive.
Trametinib blocks MEK, part of the MAPK signaling pathway that drives cell proliferation and inflammation.
The combination reduced inflammation in muscle, brain, kidney, and spleen.
Mice receiving both drugs developed fewer tumors, maintained better immune balance, and showed synergistic gene expression changes.
Your Action:
This therapy is experimental in humans, but you can act now:
Eat in ways that naturally lower mTOR activity, such as moderate protein intake and time-restricted eating.
Support MEK-regulated pathways with consistent endurance exercise and healthy glucose control.
Stay informed about clinical trials involving geroprotective drug combinations.
Bottom Line:
Targeting both mTOR and MEK unlocks a powerful synergy, one that could push the boundaries of healthy lifespan.
Source:
The geroprotectors trametinib and rapamycin combine additively to extend mouse healthspan and lifespan, Nature Aging, Lisonia Gkioni et al., Max Planck Institute for Biology of Ageing, May 28, 2025
https://www.nature.com/articles/s43587-025-00876-4
How was today’s newsletter?
LEARN MORE ABOUT OUR WORK
— Capilli Eternal
Disclaimer:
‘This newsletter is for informational purposes only and does not substitute professional medical advice. Always consult with a healthcare provider before making any changes to your health regimen.